慢性粒细胞白血病的治疗新进展

Chronic myeloid leukemia:new development in therapy

慢性粒细胞白血病(chronicmyelogenousleukemia,CML)是以粒系增生为主要表现的恶性克隆性疾病。以往CML的常规治疗包括羟基脲、马利兰、靛玉红及甲异靛、干扰素、联合化疗及造血干细胞移植等。近年来,CML的治疗在以往的基础上有了长足的进展,其中以bcr-ab融合基因及其具有酪氨酸激酶活性的蛋白产物为靶向的酪氨酸激酶抑制剂Imatinib是近年来CML治疗最重要的进展,此外在干扰素及干细胞移植治疗方面亦有了新的认识。CML的治疗已发展为一个复杂而有序的系统。本文就近年来CML治疗方面的进展进行综述。

Chronic myloid leukemia （CML） is a clonal hematopoietic stem cell disorder, characterized by granulocytic leukocytosis and immaturity. The classical treatment of CML includes Hydroxyurea, Bulsulfan, Interferon -α, combination chemotherapy, hemotapoietic stem cell transplantation and the forth. During the late years, through rational drug development, STI571, a bcr - abl tyrosine kinase inhibitor, has emerged as targeted therapy that offers new hope for expanded treatment options for patients with CML. Therapy of CML have developed to a complicated but integrated system now. In this review, we will summarize the new development in CML therapy, and introduce how to make a treatment plan to a specific patient.